Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: back pain

Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19

Megan Brooks  |  June 23, 2020

NEW YORK (Reuters Health)—Patients with some inflammatory rheumatic conditions are at higher risk for hospital-diagnosed COVID-19 infection compared with the general population, but it depends on the condition and therapy used to treat it, according to a study from Spain. It’s now clear that older patients and those with some common diseases are at increased…

Filed under:Conditions Tagged with:coronavirusCOVID-19Rheumatic Disease

Basilisks in Rheumatology: The Hunt for Rheumatic Mysteries Shrouded in Enigmas & Wrapped in Puzzles

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  June 23, 2020

What do rheumatology and wizardry have in common? More than you may think. Like basilisks, rheumatic diseases are often elusive and changing in presentation…

Filed under:Professional Topics

More Evidence Links Pediatric Inflammatory Multisystem Syndrome to SARS-CoV-2

Will Boggs, MD  |  June 18, 2020

NEW YORK (Reuters Health)—Two new reports in JAMA strengthen the link between SARS-CoV-2 infection and pediatric inflammatory multisystem syndrome (PIMS). Pediatricians from several communities have reported children who developed fever and multisystem inflammation during the COVID-19 pandemic. Some children were critically ill and some had characteristics similar to Kawasaki disease or Kawasaki disease shock syndrome….

Filed under:ConditionsPediatric Conditions Tagged with:ChildrenCOVID-19Kawasaki diseasePediatricpediatric inflammatory multisystem syndrome (PIMS)

A Peaceful Medical Mission in Guatemala, Days before COVID-19

Daniel F. Battafarano, DO, MACP, FACR  |  June 15, 2020

My first-ever medical mission trip, after 37 years of medical practice, was to Teleman, Alta Verapaz, Guatemala. Prior to the trip, my excitement as an adult-trained rheumatologist was balanced against my apprehension about witnessing new diseases, caring for children and practicing in an austere environment with limited medical resources. As directed by the travel clinic,…

Filed under:Career Development Tagged with:medical missionsVolunteering

Case Report: Which Vasculitis Is It?

Mary Buckley, MD, & Jeffrey Dvergsten, MD  |  June 15, 2020

A 13-year-old, adopted girl of unknown ancestry with social anxiety, selective mutism and Takayasu arteritis presented for evaluation of severe, painful, gingival hyperplasia, which limited her oral intake and resulted in weight loss. The young patient was diagnosed with Takayasu arteritis at age 8, when she presented with a persistently elevated erythrocyte sedimentation rate (ESR),…

Filed under:ConditionsVasculitis Tagged with:Behçet’s diseasecase reportTakayasu arteritis (TAK)

Novel Cathepsin K Inhibitor Promising for OA

Lara C. Pullen, PhD  |  June 10, 2020

Research into the disease-modifying effects of the novel cathepsin K inhibitor MIV-711 suggests it may be effective as a knee OA treatment. In OA patients using the treatment, the study documented statistically significant reductions in bone and cartilage progression…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:cathepsin-K inhibitorKnee Osteoarthritis (OA)OsteoarthritisPain

FDA Approves Celecoxib in an Oral Solution

Michele B. Kaufman, PharmD, BCGP  |  June 8, 2020

The FDA has approved a 25 mg/mL dose of an oral solution of celecoxib to treat adults with acute migraine…

Filed under:AnalgesicsDrug Updates Tagged with:celecoxib (Elyxyb)FDAPain ManagementU.S. Food and Drug Administration (FDA)

In the Lungs: Asthma & COPD May Be Early, Independent Risk Factors for RA

Carina Stanton  |  June 1, 2020

Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…

Filed under:ConditionsRheumatoid Arthritis Tagged with:2019 ACR/ARP Annual Meetingasthmachronic obstructive pulmonary disorderCOPDlungs

Driving through the Storm: A Pediatric Rheumatologist Finds a Pandemic of Rheumatic Disease

Mark Gorelik, MD  |  May 18, 2020

A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.

Filed under:ConditionsOpinionSpeak Out Rheum Tagged with:COVID-19Pediatrics

Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

Lara C. Pullen, PhD  |  May 18, 2020

Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…

Filed under:ConditionsPsoriatic Arthritis Tagged with:apremilastcDAPSAClinical Disease Activity in Psoriatic Arthritis (cDAPSA)PsAPsoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 70
  • 71
  • 72
  • 73
  • 74
  • …
  • 162
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences